Core Viewpoint - Quantum BioPharma Ltd. announced that its licensee, Celly Nutrition Corporation, is raising up to 250 million, after which the royalty rate drops to 3% indefinitely [2][5]. Product Details - unbuzzd is a scientifically-backed beverage that accelerates alcohol metabolism, restores mental clarity, and alleviates hangover symptoms, appealing to consumers who wish to enjoy alcohol responsibly [7][8]. - Clinical trials demonstrated that unbuzzd reduces blood alcohol concentration (BAC) by over 40% faster than a placebo within 30 minutes, improves alertness, stabilizes heart rate and blood pressure, and significantly reduces hangover symptoms [14]. Strategic Developments - Celly Nutrition has engaged a leading New York investment bank to assist with financial advisory services and to manage a proposed public offering, indicating a strategic move towards expanding its market presence [3][6]. - The CEO of Celly Nutrition emphasized the importance of this capital raise for accelerating marketing and sales development of unbuzzd, reflecting the company's growth strategy [3].
Quantum Biopharma Licensee Celly Nutrition Retains Leading New York Investment Bank to Advise on Capital Raise and Possible Initial Public Offering Following Highly Positive Results from unbuzzd™ Clinical Study